Objective: The triple negative breast cancer patients has higher rates of local reccurence and distant metastasis and poorer survival.How to improve the treatment benefits for this group is becoming the focus for oncologists.Our aim is to detect whether surgical bed boost for triple negative breast cancer patients is associated with a difference in local failure rates and overall survival.Methods: We retrospectively reviewed the medical records of 40 cases of triple negative patients out of 399 consecutive breast cancer patients who were treated with adjuvant radiotherapy between 2004 and 2008 at our institution.Twenty cases receive a boost and twenty cases did not.No boost patients receive total dose of EBRT of 42.4-50Gy/16-25 fractions.Patients in the boost group received an additional 10-15 Gy/4-6 fractions to the tumor bed.There is no difference with T stage, surgery type and margin states (P > 0.001).The T stage:T0 7(17.5%) ;T1 7(17.5%) ;T2 20(50%) ;T3 3(7.5%) ;T4 3(7.5%).The lumpectomy in different stage is 85.7%, 85.7% ,90.0% ,66.7% ,66.7% retrospectively.The clear margin in each group is 85.7% ,85.7% ,85.7% ,90%, 100% ,66.7% retrospectively.Our observed outcomes were overall survival(OS), disease-free survival(DFS), local(LFR) and distant failure rates (DFR) using the statastatsitical software.Results:The median follow-up from date of diagnosis was 53.5 months (44.0-63.0 months).The OS for boost and no boost was 90% vs.85% and the DFS was 70% vs.70% for triple-negative subtypes.There was no difference between the two groups (P > 0.01).There was also no difference in local and distant failure rates respectively 85% vs.70% and 85 % vs.75% (P > 0.01).Conclusions:In our series, radiotherapy boost does not appear to improve local control and overall survivalin triple negative breast cancer.This warrants further nestigations.